论文部分内容阅读
目的了解进展期胃癌术中行区域性缓释化疗的方法及临床疗效与不良反应情况。方法将郑州市第二人民医院120例进展期胃癌患者随机分为两组,治疗组60例:行胃癌根治术(D2),术中行区域性缓释化疗药物5-FU缓释剂的应用。对照组60例:术中动脉灌注化疗(IAIC)的应用。治疗后对其两组患者的并发症及药物不良反应进行对比分析,并对所有患者进行随访了解术后复发情况。结果治疗组60例共出现并发症6例(10%),对照组60例共有18例出现并发症(30%)。两组1年生存率比较无显著差异性(P>0.05)。两组2年、3年生存率比较有显著差异性(P<0.05)。结论进展期胃癌术中行区域性缓释化疗与术中动脉灌注化疗其疗效显著,但术中行区域性缓释化疗更为直接,其药物不良反应较少。
Objective To investigate the method and clinical efficacy and adverse reactions of regional sustained-release chemotherapy in advanced gastric cancer. Methods A total of 120 patients with advanced gastric cancer from the Second People’s Hospital of Zhengzhou City were randomly divided into two groups. The treatment group (60 cases) underwent radical gastrectomy (D2) and the application of 5-FU regional sustained release chemotherapy drug. Control group of 60 cases: intraoperative arterial infusion chemotherapy (IAIC) application. After treatment, the complication and adverse drug reactions of the two groups were compared and analyzed, and all the patients were followed up to understand the postoperative recurrence. Results Sixty patients (10%) had complications in the treatment group and 18 patients in the control group (30%). There was no significant difference in one-year survival rate between the two groups (P> 0.05). Two-year, three-year survival rates were significantly different (P <0.05). Conclusions Regional delayed-release chemotherapy and intra-arterial infusion chemotherapy are effective in advanced gastric cancer. However, regional delayed-release chemotherapy is more direct and less adverse drug reactions.